Study on the value of dulaglutide combined with Bifidobacterium quadruple live bacterial tablets in reducing the risk of cardiovascular disease in patients with type 2 diabetes mellitus

Tian Jinxia; Yang Yanfei; Yu Zijuan; Zong Xiaochun

doi:10.3760/j.issn.1673-4777.2025.02.011

Abstract：Objective To explore the value of dulaglutide combined with Bifidobacterium quadruple live bacterial tablets in reducing the risk of cardiovascular diseases in patients with type 2 diabetes mellitus(T2 DM).Methods A total of 60 patients with T2DM admitted to the Department of Endocrinology,Zhangjiakou First Hospital,Hebei Province from March 2021 to March 2022 were selected as the research objects.According to the random number table method,they were divided into control group and observation group,with 30 cases in each group.The control group was treated with conventional drugs,and the observation group was treated with dulaglutide combined with Bifidobacterium quadruple live bacterial tablets on the basis of the control group.Both groups received diet and exercise intervention.The blood glucose level,islet function index and inflammatory factor index of the two groups were detected,and the risk of cardiovascular disease was compared between the two groups.Results After treatment,the fasting blood glucose,glycosylated hemoglobin and average blood glucose levels of the two groups were lower than those before treatment,and the blood glucose level of the observation group was lower than that of the control group(all P＜0.05).After treatment,the steady-state model islet β cell function index,0.5 h insulin production index and 2 h insulin production index of the two groups were higher than those before treatment,and the steady-state model insulin resistance index was lower than that before treatment;compared with the control group,the observation group had greater changes(all P＜0.05).After treatment,the levels of interleukin-6,high-sensitivity C-reactive protein and lipopolysaccharide in the two groups were lower than those before treatment,and the levels of each index in the observation group were lower than those in the control group(all P＜0.05).After treatment,the Framingham risk score and 10-year risk of cardiovascular disease in the observation group were lower than those before treatment,and lower than those in the control group[(12.0±0.6)vs(13.1±0.8),(4.1±2.3)％vs(6.2±5.3)％](all P＜0.05).Conclusion Dulaglutide combined with Bifidobacterium quadruple live bacterial tablets in the treatment of T2DM can reduce insulin resistance,improve islet β cell function,control inflammatory response,and reduce the risk of cardiovascular events.